Your browser doesn't support javascript.
loading
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions
Costa Jr, J Ribamar; Abizaid, Alexandre; Costa Jr, José Ribamar; Feres, Fausto; Tanajura, Luis Fernando; Abizaid, Andrea; Maldonado, Galo; Staico, Rodolfo; Siqueira, Dimytri; Sousa, Amanda; Bonan, Raoul; Sousa, Eduardo.
Afiliação
  • Costa Jr, J Ribamar; Instituto Dante Pazzanese de Cardiologia. BR
  • Abizaid, Alexandre; Instituto Dante Pazzanese de Cardiologia. BR
  • Costa Jr, José Ribamar; Instituto Dante Pazzanese de Cardiologia. BR
  • Feres, Fausto; Instituto Dante Pazzanese de Cardiologia. BR
  • Tanajura, Luis Fernando; Instituto Dante Pazzanese de Cardiologia. BR
  • Abizaid, Andrea; Instituto Dante Pazzanese de Cardiologia. BR
  • Maldonado, Galo; Instituto Dante Pazzanese de Cardiologia. BR
  • Staico, Rodolfo; Instituto Dante Pazzanese de Cardiologia. BR
  • Siqueira, Dimytri; Instituto Dante Pazzanese de Cardiologia. BR
  • Sousa, Amanda; Instituto Dante Pazzanese de Cardiologia. BR
  • Bonan, Raoul; MIV Therapeutics. CA
  • Sousa, Eduardo; Instituto Dante Pazzanese de Cardiologia. BR
JACC Int ; 02: 422-427, 2009.
Article em En | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1064026
Biblioteca responsável: BR79.1
Localização: BR79.1
RESUMO
Objectives We sought to assess the safety and efficacy of the novel VESTAsync-eluting stent (MIVTherapeutics, Atlanta, Georgia) combining a stainless steel platform with a nanothin-microporoushydroxyapatite surface coating impregnated with a polymer-free low-dose of sirolimus (55 g). Background Durable polymers in first-generation drug-eluting stents (DES) have been linked to local inflammatory reaction leading to a positive vessel remodeling, late incomplete stent apposition,and in some cases, stent thrombosis. The removal of the polymer from the DES system could increase the safety profile of this novel technology.Methods A total of 15 patients with single de novo lesions in native coronary arteries with 3.0- to 3.5-mm diameter and 14-mm length were enrolled in this first-in-man study. Primary end pointwas in-stent late lumen loss (LL) at 4 and 9 months. Results Baseline characteristics included mean age of 63 years and 33% of diabetics. Reference vessel diameter and lesion length were 2.7 0.3 mm and 10 2.0 mm, respectively. Procedure successwas obtained in all cases. Lifelong aspirin and 5-month clopidogrel treatment were prescribed to all patients. At 4 months, in-stent LL and percentage of neointimal hyperplasia were 0.3 0.25 mm and 2.6 2.2%, respectively, with a nonsignificant increase at 9 months (0.36 0.23 mm and 4.0 2.2%, respectively). Serial intravascular ultrasound did not show late incomplete stent apposition.There were no major adverse cardiac events within 1 year of follow-up.Conclusions The novel VESTAsync-eluting stent was effective in reducing LL and neointimal hyperplasia at 4 and 9 months, with no evidence of late catch-up by quantitative coronary angiographyor intravascular ultrasound. (J Am Coll Cardiol Intv 2009;2422–7) © 2009 by the American College of Cardiology Foundation From...
Assuntos
Buscar no Google
Coleções: 06-national / BR Base de dados: SES-SP / SESSP-IDPCPROD Assunto principal: Stents / Sirolimo / Traumatismos Cardíacos Idioma: En Revista: JACC Int Ano de publicação: 2009 Tipo de documento: Article
Buscar no Google
Coleções: 06-national / BR Base de dados: SES-SP / SESSP-IDPCPROD Assunto principal: Stents / Sirolimo / Traumatismos Cardíacos Idioma: En Revista: JACC Int Ano de publicação: 2009 Tipo de documento: Article